

PROSPECTUS SUPPLEMENT
(to Prospectus dated March 8, 2016)

Up to \$3,352,699 of Shares



Common Stock

This prospectus supplement updates and amends certain information contained on the cover page of the prospectus supplement, dated March 8, 2016, to the prospectus dated March 8, 2016 (together referred to as the “2016 prospectus”), relating to the offer and sale of shares of our common stock through Cowen and Company, LLC (“Cowen”), as sales agent for an “at the market offering” program (“ATM Program”). In accordance with the terms of the sales agreement, dated February 3, 2016, we may offer and sell up to a maximum of \$50,000,000 of shares of our common stock from time to time through Cowen as our sales agent. Of this amount, at September 7, 2017, \$44,669,054 remains available for issuance under the ATM Program. Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. This prospectus supplement should be read in conjunction with the 2016 prospectus, and is qualified by reference to the 2016 prospectus, except to the extent that the information presented herein supersedes the information contained in the 2016 prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the 2016 prospectus, including any amendments or supplements thereto.

Through September 7, 2017, we have sold 1,095,378 shares of our common stock through Cowen under the sales agreement. We are filing this prospectus supplement to amend the 2016 prospectus because we are now subject to General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the 2016 prospectus are a part. As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to \$3,352,699 from time to time through Cowen. If our public float increases such that we may sell additional amounts under the sales agreement and the registration statement of which this prospectus supplement and the 2016 prospectus are a part, we will file another prospectus supplement prior to making additional sales.

Our common stock is quoted on the Nasdaq Global Market (the “Exchange”), under the symbol “AVGR.” On September 7, 2017, the last reported sale price of our common stock was \$0.32 per share. The aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is \$10,058,097, which was calculated based on 22,252,428 shares of our common stock outstanding held by non-affiliates and at a price of \$0.452 per share, the closing price of our common stock on August 8, 2017, a date that is within 60 days of filing this prospectus supplement. As of the date hereof, we have not offered or sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.

Investing in our common stock involves significant risks. See “Risk Factors” beginning on page S-4 of the 2016 prospectus and under the heading “Risk Factors” included in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, and any amendments thereto, which are incorporated by reference into the 2016 prospectus.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement or the 2016 prospectus. Any representation to the contrary is a criminal offense.

Cowen

September 8, 2017
